Navigation Links
TGen President Dr. Jeffrey Trent speaks at Brookings Institution biomedical conference
Date:7/15/2013

WASHINGTON, D.C. July 15, 2013 Dr. Jeffrey Trent, President and Research Director for the Translational Genomics Research Institute (TGen), will discuss state-of-the-art genomics research July 16 at the Brookings Institution.

Dr. Trent, Ph.D., F.A.C.M.G., and former Scientific Director of the National Human Genome Research Institute, is part of a panel, Innovation in Action, at Brookings' 2nd annual State of Biomedical Innovation Conference, which will focus on the use of novel data sources to improve medical product development and care delivery.

Specifically, Dr. Trent will discuss TGen's ongoing work in translating genomics research into clinical benefit. TGen is one of a very few centers who are using the entire human genome in clinical trials in order to diagnose or make treatment decisions for an individual patient (precision medicine).

"The human genome will be the medical textbook for the next century and beyond," Dr. Trent said. "By harnessing the power of the human genome, we will provide immeasurable patient benefit while at the same time reducing the time and costs of diagnosis and treatment. TGen is a global leader in clinical trials that deploy this form of innovative research."

TGen's translational model enables pioneering discoveries in the laboratory to be quickly moved to clinical trials where they can be used to immediately benefit patients with many types of cancer and other debilitating diseases.

Dr. Trent's panel will be moderated by Dr. Mark B. McClellan, Director and Fellow of Brookings' Initiative on Innovation and Value in Health Care. He is the former administrator for the Centers for Medicare and Medicaid Services (2004-2006), and the former commissioner of the Food and Drug Administration (2002-2004). He also served as a member of the President's Council of Economic Advisers, and as senior director for health care policy at the White House (2001-2002). In these positions, he developed and implemented major reforms in health policy.

This conference is being convened by the Engelberg Center for Health Care Reform at Brookings, which was established to help turn ideas for health care reform into action, including reducing gaps in insurance coverage and ensuring health care affordability. Its mission is to develop data-driven, practical policy solutions that promote broad access to high-quality, affordable and innovative care in the United States. The Center also conducts research, makes policy recommendations, and facilitates development of new consensus around key issues, providing technical support to implement and evaluate new solutions in collaboration with a broad range of stakeholders.

The conference is scheduled for 9 a.m.-12:30 p.m. EDT July 16 at the Brookings Institution, Falk Auditorium, 1775 Massachusetts Avenue, N.W., Washington, D.C. Dr. Trent's hour-long panel is scheduled to start at 10:10 a.m. The event will be streamed live on the Brookings website: http://www.brookings.edu/events/2013/07/16-biomedical-innovation.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA
2. Homeland Security Corporation (HSCC) Appoints New President with Biometrics and Access Control Solutions Expertise and Contacts
3. Statement by WCS president and CEO on historic CITES ruling
4. FASEB joins President Obama in urging Congress to sustain investments in research and innovation
5. Bluemetal Architects appoints David Le Penske as Vice President of Health & Life Sciences
6. President Obama honors MU researcher with National Medal of Science
7. ONR-funded young innovators recognized by President
8. NASA Goddard scientist receives Presidential Early Career Award
9. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
10. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
11. President, CEO Leppävuori, VTT: Finland should create a national bioeconomy strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2019)... ... September 25, 2019 , ... Modality ... ranked No. 3094 on Inc. Magazine’s annual Inc. 5000 list, the most prestigious ... of 120 percent. Based on this growth, the Houston-based firm also ranked No. ...
(Date:9/24/2019)... (PRWEB) , ... September 23, 2019 , ... ... offices in Cambridge, MA, announce today that Holotype HLA and other Omixon products ... meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in ...
(Date:9/24/2019)... , ... September 24, 2019 , ... ... to announce that it has received 300 five-star reviews on the popular travel ... “perfect team-building experience,” “amazing views and incredible food” and “unique local experience.” These ...
Breaking Biology News(10 mins):
(Date:9/24/2019)... ... 2019 , ... Personalized Stem Cells, Inc (“PSC”), ... clinical trial sites and physician investigators. The clinical trial sites are now ... Clinical trial sites are currently located in San Diego and Los Angeles California, ...
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... ... that Julie Delaney, Director, Project and Clinical Supplies Management, Asia Pacific (APAC) will ... One Farrer Hotel, Singapore, on Sept. 25-26, 2019. , On Thursday, Sept. 26, ...
(Date:9/17/2019)... ... 16, 2019 , ... When a lot of researchers think of Visikol, they ... 3D characterization of tissues through the use of confocal and light sheet microscopy. However, ... advanced cell culture focused contract research organization and today offers 3D tissue imaging ...
(Date:9/11/2019)... , ... September 09, 2019 , ... ... (IRT) for clinical trial randomization and drug supply chain management, today announced its ... the global life sciences industry. , “The integration between Veeva Vault EDC and ...
Breaking Biology Technology: